Summary
The claim is not verifiable because the supplied FDA label content for '1 INDICATIONS AND USAGE' contains no indication text.
Category Scores
Accurate Statements
Unsupported Statements
Opdivo (nivolumab) is available and approved in the European Union for multiple cancer indications.
The provided materials include only the label section heading '1 INDICATIONS AND USAGE' with no accompanying FDA label text. Therefore, the statement about indications and EU approval cannot be supported or verified from the supplied label content.
Contradictions
Important Omissions
FDA label indication information (and any jurisdiction-specific approval statements, if present) from '1 INDICATIONS AND USAGE'.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No dosing, contraindications, warnings, or safety-related instructions were claimed; the issue is lack of label support/verification for the jurisdiction and indication scope.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
The claim cannot be verified because no FDA label indication content was provided in the supplied materials.
Suggested Improvement
Provide the actual FDA label text under '1 INDICATIONS AND USAGE' to support the specific indication(s) and scope; avoid asserting EU-specific approval if the supplied FDA label content does not contain that information.